Aveanna Announces Second Quarter 2025 Earnings Release Date and Conference Call
The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available three hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13754011. The replay will be available until August 14, 2025.
Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of the Company's website at https://ir.aveanna.com/. The online replay will be available for one week following the call.
About Aveanna Healthcare
Aveanna Healthcare is headquartered in Atlanta, Georgia and has locations in 36 states providing a broad range of pediatric and adult healthcare services including nursing, rehabilitation services, occupational nursing in schools, therapy services, day treatment centers for medically fragile and chronically ill children and adults, home health and hospice services, as well as delivery of enteral nutrition and other products to patients. The Company also provides case management services in order to assist families and patients by coordinating the provision of services between insurers or other payers, physicians, hospitals, and other healthcare providers. In addition, the Company provides respite healthcare services, which are temporary care provider services provided in relief of the patient's normal caregiver. The Company's services are designed to provide a high quality, lower cost alternative to prolonged hospitalization. For more information, please visit www.aveanna.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
22 minutes ago
- Cision Canada
DeFi Technologies Announces Commencement of Options Trading on Nasdaq
TORONTO, July 21, 2025 /CNW/ - DeFi Technologies Inc. (the " Company" or " DeFi Technologies") (Nasdaq: DEFT) (CBOE CA: DEFI) (GR: R9B), a financial technology company bridging the gap between traditional capital markets and decentralized finance, today announced that the Company's common stock is now available for options trading on the Nasdaq Options Market ("Nasdaq"). Trading in DeFi Technologies' options commenced on June 21, 2025 under the ticker symbol "DEFT" and include a range of standard expiration dates and strike prices. This listing of options is expected to expand investor access and may enhance liquidity in the Company's shares, providing investors with added flexibility to manage risk, leverage positions and express views on the Company's future stock performance. DeFi Technologies believes this milestone reflects continued growth in investor interest and confidence in the Company's long-term strategic outlook. Options trading on DeFi Technologies is available through the Options Clearing Corporation ("OCC") and will be subject to standard rules and regulations established by Nasdaq and the OCC. About DeFi Technologies DeFi Technologies Inc. (Nasdaq: DEFT) (CBOE CA: DEFI) (GR: R9B) is a financial technology company bridging the gap between traditional capital markets and decentralized finance (" DeFi"). As the first Nasdaq-listed digital asset manager of its kind, DeFi Technologies offers equity investors diversified exposure to the broader decentralized economy through its integrated and scalable business model. This includes Valour, which offers access to over sixty-five of the world's most innovative digital assets via regulated ETPs; Stillman Digital, a digital asset prime brokerage focused on institutional-grade execution and custody; Reflexivity Research, which provides leading research into the digital asset space; Neuronomics, which develops quantitative trading strategies and infrastructure; and DeFi Alpha, the Company's internal arbitrage and trading business line. With deep expertise across capital markets and emerging technologies, DeFi Technologies is building the institutional gateway to the future of finance. Follow DeFi Technologies on LinkedIn and X/Twitter, and for more details, visit DeFi Technologies Subsidiaries About Valour Valour Inc. and Valour Digital Securities Limited (together, " Valour") issues exchange traded products (" ETPs") that enable retail and institutional investors to access digital assets in a simple and secure way via their traditional bank account. Valour is part of the asset management business line of DeFi Technologies. For more information about Valour, to subscribe, or to receive updates, visit About Stillman Digital Stillman Digital is a leading digital asset liquidity provider that offers limitless liquidity solutions for businesses, focusing on industry-leading trade execution, settlement, and technology. For more information, please visit About Reflexivity Research Reflexivity Research LLC is a leading research firm specializing in the creation of high-quality, in-depth research reports for the bitcoin and digital asset industry, empowering investors with valuable insights. For more information please visit About Neuronomics AG Neuronomics AG is a Swiss asset management firm specializing in AI-powered quantitative trading strategies. By integrating artificial intelligence, computational neuroscience and quantitative finance, Neuronomics delivers cutting-edge solutions that drive superior risk-adjusted performance in financial markets. For more information please visit Analyst Coverage of DeFi Technologies A full list of DeFi Technologies analyst coverage can be found here: For inquiries from institutional investors, funds, or family offices, please contact: ir@ Cautionary note regarding forward-looking information: This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to the commencement of option trading on the NASDAQ; the potential benefits of the option trading on NASDAQ; the Company's business and future growth prospects; the regulatory environment with respect to the growth and adoption of decentralized finance; the pursuit by the Company and its subsidiaries of business opportunities; and the merits or potential returns of any such opportunities. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Such risks, uncertainties and other factors include, but is not limited to the acceptance of Valour exchange traded products by exchanges; growth and development of decentralised finance and digital asset sector; rules and regulations with respect to decentralised finance and digital assets; fluctuation in digital asset prices; general business, economic, competitive, political and social uncertainties. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.
National Post
22 minutes ago
- National Post
Invest in Precision: Mitutoyo America Corporation Announces Limited-Time Savings on MiSTAR 555 and 575 Coordinate Measuring Machines
Article content Sorry, your browser doesn't support embedded videos. Article content AURORA, Ill. — In today's unpredictable economy, one investment still delivers lasting certainty: Precision is the smartest investment. For a limited time, Mitutoyo America Corporation, the trusted leader in advanced metrology solutions, is offering a rare opportunity to invest in the future success of your inspection capabilities with exclusive promotional pricing of up to 26 percent off the MiSTAR 555 and 575 CMM through September 30, 2025. Article content Article content 'The MiSTAR CMM is built to thrive on the shop floor. It is rugged, reliable and fully adaptable to your machining process. With this exclusive promotion, you're not just getting precision, you're getting value with savings of up to 26 percent.' Article content Mitutoyo's MCOSMOS software scales to meet your inspection needs, from basic measurement and reporting with MCOSMOS-1, to CAD model part programming with free-form surface evaluation MCOSMOS-2 and MCOSMOS-3 adds scanning of 2D line and 3D surface profiles with CAD model analysis. Article content Three configurations offered: Article content BASIC model type- PH6 TP20 probing and MCOSMOS-1 software for small shops with essential digital routines Advanced model type- PH6M SP25 probe and MCOSMOS-2 software for growing operations who require CAD model part programming with free-form surface evaluation. Ultimate model type- PH10 SP25 MCOSMOS-3 software for high-throughput environments Article content The Mitutoyo MiSTAR CMM delivers reliable performance across a broad range of operating environments with guaranteed accuracy from 10 °C to 40 °C, and enhanced capability within narrower ranges of 10 °C to 30 °C and 18 °C to 22 °C. Article content Each MiSTAR configuration is delivered ready for immediate operation and includes: Article content When accuracy matters, manufacturers turn to Mitutoyo for proven performance that drives quality forward. Contact your local Mitutoyo representative or distributor to schedule a demo, consultation, or get a quote. Article content At Article content , precision is our profession. We are the leader in metrology instruments, solutions and support, offering more than 5,500 products, the largest and most comprehensive product portfolio of any commercial metrology provider. Mitutoyo also has the highest-performing A2LA-accredited calibration laboratories (A2LA Certificate No. 0750.01) in the nation. For more information, contact the Mitutoyo inside sales team at Article content Article content Article content Article content Article content Contacts
CTV News
22 minutes ago
- CTV News
Weight loss medications like Ozempic linked to eating disorders in boys and men: study
Prescription weight loss medication use has been linked to significantly higher rates of eating disorders in adolescent boys and men, according to a new study. Led by Kyle Ganson, an assistant professor at the University of Toronto's faculty of social work, the study focuses on an often overlooked population and raises new concerns about the use of high-profile medications like Ozempic and Wegovy for weight loss. 'While these medications are typically prescribed for diabetes or obesity, their off-label use for weight loss has become popular,' Ganson said in a news release from the University of Toronto. 'Our findings underscore potential psychological implications for young men.' The study analyzed survey data from 1,543 boys and men from Canada and the U.S. who were between the ages of 15 and 35. While only 1.2 per cent of the sample reported using prescription weight loss medication in the past 12 months, they were much more likely to report eating disorder attitudes and behaviours than others, such as loss of control while eating (63.2 per cent versus 36.2 per cent), binge eating (63.2 per cent versus 34.1 per cent) and purging via vomiting (15.8 per cent versus 5.6 per cent). The study also found that boys and men who used the medication were typically older, had a higher body mass index, and were more likely to identify as not being white or heterosexual. 'Boys and men are frequently left out of the conversation about eating disorders and body image pressures, but this study makes clear that they are not immune to the risks,' Ganson said. The study was published earlier this month in the journal Eating Behaviors. 'There is a greater need to describe the prevalence of use among understudied populations, as well as identify associations with eating disorder attitudes and behaviours,' the study explained. 'Health and mental health care professionals should be cognizant of the associations found in this study to ensure proper eating disorder assessment and intervention are provided to individuals, including boys and men, who use prescription weight loss medication.'
